Abstract:Background: Plasma cell-free RNA (cfRNA) holds promise for non-invasive cancer biomarker discovery, particularly in diseases like prostate cancer where specific biomarkers (AR splicing variants and TMPRSS2:ERG fusion) are detectable at the RNA level. Despite its potential, the technical challenges posed by blood cell-originated cfRNA abundance necessitates the development of robust and reliable assays for non-invasive cancer diagnostics. This study establishes and demonstrates the clinical utility of an innovative protocol for isolating and identifying tumor-originated cfRNA in plasma samples. Methods: A novel methodology was developed for the simultaneous extraction of cfDNA and cfRNA from a single blood sample tube, enabling whole transcriptome sequencing (WTS) analysis with minimal input as low as 1ng. A proprietary method was developed to selectively deplete blood cell-originated transcripts in the library. An enrichment-based WTS assay was conducted, and a customized RNASeq analysis pipeline was employed to enable expression profiling and cancer biomarker testing from the cfRNA samples. Results: The developed extraction method yielded substantial amounts of cfDNA and cfRNA from a 4 mL blood sample. Efficient depletion of blood cell-originated transcripts, achieving over 99% removal, enhanced the detection of a broader range of gene expressions in plasma. Implementation of the cfRNA WTS assay across healthy donor and cancer samples demonstrated consistency with documented biomarker status. The assay revealed significant differential clustering between cancer samples and healthy donors, with characteristic cancer genes contributing to the distinction. Reproducibility and analytical sensitivity of the developed cfRNA WTS assay were successfully validated. Conclusions: This study introduces Predicine's proprietary cfRNA WTS assay, enabling concurrent expression profiling and RNA biomarker detection in plasma samples. Overcoming technical challenges associated with blood cell-originated cfRNA, this assay represents a significant advancement in liquid biopsy-based cancer diagnostics. Citation Format: Fang Liu, Yong Huang, Min Wang, Xiangying Sun, Binggang Xiang, Shidong Jia, Pan Du, Shujun Luo. Innovative blood-based cell-free RNA whole transcriptome sequencing for comprehensive RNA profiling in patient plasma samples and its clinical applications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2302.

Protocol for analyzing plasma cell-free DNA fragment end motifs from ultra-low-pass whole-genome sequencing

Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA

FinaleToolkit: Accelerating Cell-Free DNA Fragmentation Analysis with a High-Speed Computational Toolkit

FinaleMe: Predicting DNA methylation by the fragmentation patterns of plasma cell-free DNA

Epigenetic Analysis of Cell-Free DNA by Fragmentomic Profiling

A Practical Approach for Targeting Structural Variants Genome-wide in Plasma Cell-free DNA

Analysis of a Cell-Free DNA-based Cancer Screening Cohort Links Fragmentomic Profiles, Nuclease Levels, and Plasma DNA Concentrations

DNA methylation analysis explores the molecular basis of plasma cell-free DNA fragmentation

Genomic origin, fragmentomics, and transcriptional correlation of long cell-free DNA molecules in human plasma

Plasma Contains Ultra-short Single-stranded DNA in Addition to Nucleosomal cfDNA

A novel approach for in vivo DNA footprinting using short double-stranded cell-free DNA from plasma

cfDNApipe: a comprehensive quality control and analysis pipeline for cell-free DNA high-throughput sequencing data

Abstract 4950: Applying fragmentomics profiles of plasma cell-free DNA for breast cancer detection

Genomic Origin, Fragmentomics, and Transcriptional Properties of Long Cell-Free DNA Molecules in Human Plasma.

Cell-free DNA end characteristics enable accurate and sensitive cancer diagnosis

Liquid footprinting: A novel approach for DNA footprinting using short double-stranded cell-free DNA from plasma

Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR

Abstract 2302: Innovative blood-based cell-free RNA whole transcriptome sequencing for comprehensive RNA profiling in patient plasma samples and its clinical applications

Plasma contains ultrashort single-stranded DNA in addition to nucleosomal cell-free DNA

Cell-free nucleic acid fragmentomics: A non-invasive window into cellular epigenomes